Summary
PROJECT SUMMARY Immunotherapies for cancer have revolutionized oncology, but most patients do not experience durable responses. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are now FDA-approved for a wide variety of tumors, but non-invasive strategies to monitor response and identify mechanisms of resistance have not yet been developed. Such approaches would allow responsive patients to remain on therapy and potentially avoid the toxicity associated with other therapies, such as chemotherapy and radiation. In addition, early identification of resistance would allow for new precision m
